1. Scrip

Vical Faced With Failure of Another Vaccine Trial

 
• By Emily Hayes

Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.

Arrows miss target

Vical Inc. will have to refocus its development efforts once again, with the mid-stage trial failure of its genital herpes therapeutic vaccine VCL-HB01. The company is ceasing development of the candidate and will put that capital toward development of its novel antifungal agent.

The herpes simplex virus (HSV)-2 vaccine candidate, developed with the company's proprietary Vaxfectin adjuvant, did not meet the primary endpoint...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 
• By Jessica Merrill

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.